爱荷华州

我们是谁

  • 2 月 5, 2024
    ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
  • 1 月 9, 2024
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
  • 1 月 9, 2024
    ERASur研究：测试在有限转移性结直肠癌的常规系统疗法基础上增加全烧蚀疗法的效果
  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • 12 月 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • 4 月 5, 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
  • 4 月 5, 2022
    治疗实体瘤患者的 Pembrolizumab 和重组白细胞介素-12
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究
  • 4 月 5, 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
  • 4 月 5, 2022
    KRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究（KRYSTAL-10）